• Rege Nephro

  Participated · Convertible Note · Jul 2026

  Rege Nephro is developing therapies for kidney disease and is advancing a clinical pipeline in the renal space. The company is preparing for clinical trials and is using interim financing to accelerate R&D and pipeline advancement. Its recent bridge financing is intended to extend cash runway and de-risk near-term development milestones ahead of a larger Series C. Rege Nephro says this capital raise is part of a longer-term strategy to strengthen its position in renal therapies. The company plans to pursue a Series C in autumn 2026 and beyond as it progresses clinical and development activities.

• Cellusion

  Participated · Equity · Jan 2022

  Cellusion is developing CLS001, an iPS cell-derived corneal endothelial cell substitute produced via a proprietary technique to efficiently generate corneal endothelial-like cells. The lead program, CLS001, targets bullous keratopathy and aims to address global corneal donor shortages that leave an estimated 13 million patients waiting for transplants. The company has reinforced its R&D organization and in September 2022 executed a license agreement with Celregen (a Fosun Pharma subsidiary) for operations in Greater China. In March 2023 a First In Human transplant of CLS001 was announced by joint research partner Dr. Shigeto Shimmura, and Cellusion is advancing preparations for company-sponsored clinical trials in Japan and for global trials. Proceeds from the recent fundraise will be used to advance those clinical-trial preparations and to support R&D of subsequent pipelines following CLS001. Cellusion is led by CEO Shin Hatou, is headquartered in Tokyo, was founded in January 2015, and has raised ¥4.5 billion (approximately US$33 million) in total to date. Cellusion develops CLS001, a corneal endothelial cell substitute (CECSi cells) differentiated from iPS cells, intended to treat bullous keratopathy and address the global shortage of donor corneas. The company highlights a simple injection delivery procedure designed to reduce reliance on donor tissue and specialized surgical expertise. Cellusion plans company-sponsored phase 1/2 clinical trials of CLS001 in Japan and overseas and has already obtained approval for an investigator-initiated first-in-human study at Keio University Hospital. The new funding will also be used to expand its Tokyo-based research and business teams and to advance R&D on other pipeline programs. Cellusion is pursuing supply-chain partnerships with Toho Holdings and Toyo Seikan Group Holdings to support CLS001 manufacturing and distribution. Founded in January 2015 and headquartered in Tokyo, the company aims to scale clinical development and global access to its cell therapy.

• Aevice Health

  Participated · Series A · Jun 2021

  Aevice Health is a Singapore-based medical technology company. Regulatory filings indicate the company has secured $7 million in a seed-plus (seed extension) funding round. The published report does not provide details about the company's specific products, services, or operating metrics. No investor names, previous rounds, valuation, or use of proceeds were disclosed in the article. The fundraising information is cited from regulatory filings reported by the publication. Aevice Health is a Singapore-based provider of remote respiratory monitoring solutions built around its flagship device, the AeviceMD. The AeviceMD is FDA-cleared and HSA-approved for remote respiratory monitoring. On 15 May 2024 the company announced a US$1.0 million investment from A&D Company to accelerate digital health initiatives. The funding is intended to support extension of AeviceMD into the US and Japan markets and further product deployment. The collaboration gives Aevice access to A&D Company's medical-technology expertise and network while allowing A&D to leverage Aevice's technology to create new healthcare solutions. JETRO Singapore fostered the partnership; the LinkedIn announcement named Adrian Ang, Rex X. Tan and the team. Aevice Health is a Singapore-based medical technology spin-off from Nanyang Technological University that develops non-invasive wearable devices for early detection of cardiopulmonary illnesses. Its flagship product, AeviceMD, is an AI-powered wearable stethoscope placed on the chest to continuously listen in real time and detect cardiopulmonary abnormalities such as wheezing. The company raised S$2.8 million (US$2.1 million) in a pre-Series A round participated by Toho Holdings, Pureland Group Venture, Silicon Solutions Partners, AIP Ventures and SEEDS Capital. Proceeds will be used to further develop its proprietary technology and expand its remote respiratory monitoring solution into Japan to augment the country’s telehealth landscape. Aevice Health has entered a strategic partnership with Tokyo-listed Toho Holdings to develop and market AeviceMD in Japan, and last year signed a partnership with The Health Bank Global to expand into the Middle East, North Africa and South Asia. The company aims to advance remote patient monitoring and enable continuous, remote self-management of chronic respiratory diseases for hospitals, insurers, pharmaceutical companies and health systems.

No current team members are available.